Genentech And Roche Showcase Trontinemab, NLRP3 Inflammasome Research And Blood-Based Diagnostics Across Integrated Pharmaceutical And Diagnostics Portfolio At AAIC

ROCHE HOLDINGS AG
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG

ROCHE HOLDINGS AG

RHHBY

0.00

ROCHE HOLDINGS AG

RHHBF

0.00

ROCHE HOLDINGS AG

RHHVF

0.00
  • Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle AD study and design of Phase III PrevenTRON study in preclinical Alzheimer’s
  • New data on Roche’s CE mark Elecsys pTau217 blood test will be presented on its use for Alzheimer's diagnosis in both primary and secondary care
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.